Ballicules.com
Withdrawn from the market (safety)

Ezogabine

POTIGA

Pronunciation: e-ZOG-a-been (poe-TEE-ga)

Ezogabine ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Ezogabine ballicule

What it isKCNQ potassium channel opener; focal seizures. Withdrawn.

Why this oneA mechanism no other antiepileptic used — opening a potassium channel rather than blocking sodium.

What limits itBlue-gray skin and retinal pigment changes ended its marketing.

Ezogabine molecular structure (skeletal formula)
Molecular structure: Ezogabine

FDA-approved for

⚠ BOXED WARNING

Classes and tags

Clinical profile

Therapeutic safety burden4 / 4
Overdose danger3 / 4
Weight-gain liability1 / 4
Sedation liability2 / 4
QT / Torsades2 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityRetinal pigmentation/vision risk, urinary retention and CNS impairment

Open Ezogabine in the interactive console ↗